Clinical trial
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV…
NCT00006436 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006436 |
|---|---|
| Title | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection |
| Official title | Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, AIDS-related, Large B-Cell, Diffuse |
| Intervention type | Biological, Drug |
| Interventions | Rituximab, Filgrastim, EPOCH |
| Enrollment | 68 |
| Start date | Jan 29, 2001 |
| Primary completion | Nov 30, 2020 |
| Completion | Jan 18, 2024 |
| First posted | Nov 6, 2000 |
| Last update posted | Dec 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: